Accolade Inc. (ACCD) stock prices were down by 0.42% as of the market closing on October 7th, 2021. This brought the price per share down to USD$39.93 at the end of the trading day. Subsequent premarket fluctuations have seen the stock dip by 7.81%, bringing it down to USD$36.81.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
Personalized Healthcare
October 7th 2021 saw ACCD stock announce financial results for the second quarter of fiscal 2021, wherein it recognized the need for a new approach to healthcare. The new approach would rectify the mistakes the existing system makes in failing to fundamentally work for patients or employers. The company announced its new Personalized Healthcare program at its recent Evolve21 customer conference. The new category is designed to enable a nationally scalable model of value-based care.
About the Platform
The Personalized Healthcare platform will require all healthcare companies to offer improved healthcare solutions. These solutions will be driven by a personalized experience and will be powered by data driven insights, while aligning the financial model of company’s with demonstrated value. ACCD stock’s new Accolade One and Accolade Care solutions serve to deliver one of the broadest offering portfolios available to employers.
ACCD Stock Acquires HealthReveal
ACCD stock also concurrently announced the completion of the acquisition of almost all of the assets of HealthReveal. HealthReveal is a clinical artificial intelligence (AI) company that focuses on ensuring that its patients receive optimal, personalized chronic care to preempt adverse outcomes. The partnering company’s technology continually applies cutting edge medical guidelines to produce Reveals. Reveals are personalized diagnostic and treatment recommendations. The incorporation of HealthReveal’s technology and expert team will accelerate the company’s focus on providing top-tier insights. These insights will be data driven, clinically based recommendations to the company’s frontline care teams of physicians, specialists, nurses, and health assistance.
ACCD Stock Builds on Success
The second quarter of fiscal 2021 saw ACCD stock begin to see the positive impact of combining Accolade, 2nd.MD and PlushCare. The teams have been integrated to function as one team across all areas, especially sales and product development. The company maintains its goal of investing in the integration between the three offerings in a bid to maintain a superlative member and customer experience.
Future Outlook for ACCD Stock
The company reported a promising quarter, as evidenced by the strength of its financial reports for the second quarter of fiscal 2021. ACCD stock is poised to capitalize on the expanded scope of opportunities afforded to it. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.
